KR20040096540A - 심혈관 질환의 예방 또는 치료를 위한 알도스테론 수용체길항제 및 알파-아드레날린성 조절제 복합 요법 - Google Patents

심혈관 질환의 예방 또는 치료를 위한 알도스테론 수용체길항제 및 알파-아드레날린성 조절제 복합 요법 Download PDF

Info

Publication number
KR20040096540A
KR20040096540A KR10-2004-7011714A KR20047011714A KR20040096540A KR 20040096540 A KR20040096540 A KR 20040096540A KR 20047011714 A KR20047011714 A KR 20047011714A KR 20040096540 A KR20040096540 A KR 20040096540A
Authority
KR
South Korea
Prior art keywords
alpha
epoxy
receptor antagonist
aldosterone receptor
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7011714A
Other languages
English (en)
Korean (ko)
Inventor
엘렌 쥐. 맥마혼
아미 이. 루돌프
Original Assignee
파마시아 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마시아 코포레이션 filed Critical 파마시아 코포레이션
Publication of KR20040096540A publication Critical patent/KR20040096540A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR10-2004-7011714A 2002-01-30 2003-01-30 심혈관 질환의 예방 또는 치료를 위한 알도스테론 수용체길항제 및 알파-아드레날린성 조절제 복합 요법 Ceased KR20040096540A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35380102P 2002-01-30 2002-01-30
US60/353,801 2002-01-30
PCT/US2003/002723 WO2003063846A2 (en) 2002-01-30 2003-01-30 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions

Publications (1)

Publication Number Publication Date
KR20040096540A true KR20040096540A (ko) 2004-11-16

Family

ID=27663255

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7011714A Ceased KR20040096540A (ko) 2002-01-30 2003-01-30 심혈관 질환의 예방 또는 치료를 위한 알도스테론 수용체길항제 및 알파-아드레날린성 조절제 복합 요법

Country Status (11)

Country Link
US (1) US20030199483A1 (enExample)
EP (1) EP1469862A2 (enExample)
JP (1) JP2005519918A (enExample)
KR (1) KR20040096540A (enExample)
CN (1) CN1625404A (enExample)
BR (1) BR0307336A (enExample)
CA (1) CA2474845A1 (enExample)
MX (1) MXPA04007472A (enExample)
PL (1) PL371437A1 (enExample)
WO (1) WO2003063846A2 (enExample)
ZA (1) ZA200405437B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100381163C (zh) * 2006-08-29 2008-04-16 陈俊云 一种含利美尼定的药物
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2016141182A1 (en) 2015-03-03 2016-09-09 Yee Richard W Compositions and methods for treating ocular diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
JP2004501099A (ja) * 2000-05-11 2004-01-15 フアルマシア　コーポレイション アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物
ES2265437T3 (es) * 2000-07-27 2007-02-16 Pharmacia Corporation Terapia de combinacion antagonista epoxi-esteroidal de aldosterona y antagonista beta-adrenergico para tratamiento de la insuficiencia cardiaca congestiva.
KR20040080439A (ko) * 2001-12-12 2004-09-18 파마시아 코포레이션 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법

Also Published As

Publication number Publication date
EP1469862A2 (en) 2004-10-27
ZA200405437B (en) 2005-07-08
WO2003063846A2 (en) 2003-08-07
US20030199483A1 (en) 2003-10-23
CN1625404A (zh) 2005-06-08
BR0307336A (pt) 2004-12-07
PL371437A1 (en) 2005-06-13
CA2474845A1 (en) 2003-08-07
WO2003063846A3 (en) 2003-12-04
JP2005519918A (ja) 2005-07-07
MXPA04007472A (es) 2004-11-10

Similar Documents

Publication Publication Date Title
KR100618466B1 (ko) 울혈성심마비의치료를위한에폭시-스테로이드계알도스테론길항제및앤지오탠신ii길항제복합요법
ES2865334T3 (es) Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
US20020042405A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
ES2312598T3 (es) Metodo para evitar ganancias de peso inducida por antipsicoticos.
JP2021042248A (ja) Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
AU2001278045A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
Marra et al. Gender-related differences in pulmonary arterial hypertension targeted drugs administration
JP2007525440A (ja) アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ
JP2007525440A6 (ja) アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ
US20030220312A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
US20040235809A1 (en) Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
WO2004100871A2 (en) Combination of an aldosterone receptor antagonist and a renin inhibitor
US20030220310A1 (en) Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
WO2004082636A2 (en) Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
US20040067918A1 (en) Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
KR20040096540A (ko) 심혈관 질환의 예방 또는 치료를 위한 알도스테론 수용체길항제 및 알파-아드레날린성 조절제 복합 요법
JP2010523512A (ja) 新規ドロスピレノン／１７β−エストラジオール投与計画、組み合わせ医薬、およびこの投与計画を行なうためのキット
US20030219401A1 (en) Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
AU2003214938A1 (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
KR20040078683A (ko) 심혈관 질환의 예방 또는 치료를 위한 알도스테론 길항제및 비스테로이드 소염제의 조합 치료법
HK1073783A (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
JP2005523302A (ja) アルドステロン受容体アンタゴニストおよびフィブリン酸誘導体の併用
Krysiak et al. Coexistence of Glucocorticoid Resistance and Pseudohypoparathyroidism.
KR20080037678A (ko) 고혈압증 치료제

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040729

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050427

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060817

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20060817

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I